Learn how PNI is leading the charge in providing an accessible solution for the discovery and development of molecularly tailored & targeted medicines at the upcoming Bloom Burton & Co. Healthcare Investor Conference scheduled for Wednesday, May 2 - Thursday, May 3, 2018.
VANCOUVER, April 30, 2018 /CNW/ - Learn how Precision NanoSystems (PNI) is leading the charge in providing an accessible solution for the discovery and development of molecularly tailored & targeted medicines at the upcoming Bloom Burton & Co. Healthcare Investor Conference scheduled for Wednesday, May 2 - Thursday, May 3, 2018.
Precision NanoSystems Presents: James Taylor, Ph.D. CEO & Co-Founder Date: Thursday, May 3, 2018 Time: 4:00 pm ET Location: Sheraton Centre Hotel Toronto, 123 Queen Street, Toronto, Ontario, M5H 2M9
“Now is truly an exciting time at the Company, marked by the achievement of three critical growth milestones in 2017. Over 200 Instruments have been deployed worldwide and we experienced record growth to include a 70% increase in our install base and 120% growth of revenue in 2017.” said James Taylor, CEO & Co-Founder PNI. “19 of the top 25 pharma are using the NanoAssemblr platform™ and PNI technology is featured in over 100 peer reviewed publications. The strong growth of both our company and customer-base highlights the potential of the NanoAssemblr platform, and our commitment to continually transform nanomedicine technologies.”
About Bloom Burton & Co. Healthcare Investor Conference
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meeting.
About Precision NanoSystems, Inc.
Precision NanoSystems Inc. (PNI) creates innovative solutions for the discovery, development and manufacture of novel nanoparticles for use as medicines and in medical research. PNI’s proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit www.precisionnanosystems.
Jane Alleva, Global Marketing Manager, Precision NanoSystems, Phone: 1 888 618 0031, ext 140, mobile: 1 778 877 5473, www.precisionnanosystems.com
SOURCE Precision Nanosystems
